Psoriasis is a chronic, immune-mediated inflammatory skin disease marked by recurrent lesions, which severely impact the quality of life of patients. While conventional treatments such as topical corticosteroids and immunosuppressants can relieve symptoms, prolonged use frequently leads to adverse effects, including skin irritation, liver toxicity, and bacterial infections. The colonization of S. aureus and its exotoxins play a key role in psoriasis pathogenesis, complicating treatment. Thus, controlling bacterial infections and toxin production is critical for improving therapeutic outcomes. In response to concerns over bacterial resistance, pyrimidine derivatives have gained significant attention due to their antibacterial, anti-inflammatory, and immunomodulatory properties. This study synthesized a series of poly tetrahydropyrimidine (PTHP) derivatives with various functional groups and backbone structures, identifying P-T-3 as the most promising candidate with excellent antimicrobial, anti-inflammatory, and biocompatible properties. Results show that P-T-3 effectively eliminates S. aureus and reduces toxin production, alleviating recurrent infections. Additionally, P-T-3 demonstrates antioxidant and anti-inflammatory effects, scavenging free radicals and reducing oxidative stress damage, enhancing psoriasis treatment. It also offers potential protection for patients on long-term immunosuppressive therapy. This presents a promising therapeutic approach for psoriasis, with the potential to enhance clinical outcomes and reduce the risk of complications.
Zhao et al. (Fri,) studied this question.